Veradigm Inc (NASDAQ:MDRX) shares traded -20.02% lower at $10.07 on Wall Street last session.
In accordance with the data, 5 analysts cover Veradigm Inc (NASDAQ:MDRX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $26.00 and a low of $13.00, we find $13.00. Given the previous closing price of $12.59, this indicates a potential upside of 3.26 percent. MDRX stock price is now -22.26% away from the 50-day moving average and -21.95% away from the 200-day moving average. The market capitalization of the company currently stands at $1.10B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
It has been rated a hold by 3 analysts and a buy by 2. Brokers who have rated the stock have averaged $16.00 as their price target over the next twelve months.
In other news, Poulton Richard J., CEO sold 10,000 shares of the company’s stock on Feb 16. The stock was sold for $173,304 at an average price of $17.33. Upon completion of the transaction, the CEO now directly owns 669,017 shares in the company, valued at $6.74 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 15, CEO Poulton Richard J. sold 10,000 shares of the business’s stock. A total of $173,835 was realized by selling the stock at an average price of $17.38. This leaves the insider owning 679,017 shares of the company worth $6.84 million. Insiders disposed of 462,157 shares of company stock worth roughly $4.65 million over the past 1 year. A total of 2.79% of the company’s stock is owned by insiders.
Veradigm Inc (NASDAQ: MDRX) opened at $12.25 on Friday. During the past 12 months, Veradigm Inc has had a low of $11.30 and a high of $19.77. As of last week, the company has a debt-to-equity ratio of 0.19, a current ratio of 3.17, and a quick ratio of 3.17. According to the stock market information, the enterprise value for the company is $826.46M, which is based on a 26.45 price-to-earnings ratio, a 3.31 price-to-earnings-growth ratio, and a beta of 0.79. The fifty day moving average price for MDRX is $12.89 and a two-hundred day moving average price translates $12.87 for the stock.
The latest earnings results from Veradigm Inc (NASDAQ: MDRX) was released for Sep, 2022. According to the Health Information Services Company, earnings per share came in at $0.23, beating analysts’ expectations of $0.19 by 0.04. This compares to -$0.03 EPS in the same period last year. The net profit margin was 6.30% and return on equity was 9.24% for MDRX. The company reported revenue of $151.92 million for the quarter, compared to $144.67 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.01 percent. For the current quarter, analysts expect MDRX to generate $167.86M in revenue.
Veradigm Inc(MDRX) Company Profile
Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
